Journal article
Vascular Function and Uric Acid-Lowering in Stage 3 CKD
Journal of the American Society of Nephrology, Vol.28(3), pp.943-952
03/2017
DOI: 10.1681/ASN.2016050521
PMCID: PMC5328166
PMID: 27620990
Abstract
Hyperuricemia may contribute to endothelial dysfunction in CKD. We evaluated whether lowering serum uric acid levels with allopurinol improves endothelial dysfunction in 80 participants ≥18 years of age with stage 3 CKD and asymptomatic hyperuricemia (≥7 mg/dl in men and ≥6 mg/dl in women) randomized in a double-blinded manner to receive placebo or allopurinol for 12 weeks. Randomization was stratified according to presence or absence of diabetes mellitus. We measured vascular endothelial function by brachial artery flow-mediated dilation. No significant differences existed between groups at baseline; 61% of the participants had diabetes mellitus in both groups. The placebo and the allopurinol groups had baseline serum uric acid levels (SDs) of 8.7 (1.6) mg/dl and 8.3 (1.4) mg/dl, respectively, and baseline flow-mediated dilation values (SDs) of 6.0% (5.0%) and 4.8% (5.0%), respectively. Compared with placebo, allopurinol lowered serum uric acid significantly but did not improve endothelial function. In participants without diabetes mellitus, allopurinol associated with a trend toward improved flow-mediated dilation (+1.4% [3.9%] versus -0.7% [4.1%] with placebo), but this was not statistically significant (
=0.26). Furthermore, we did not detect significant differences between groups in BP or serum levels of markers of inflammation and oxidative stress. In conclusion, allopurinol effectively and safely lowered serum uric acid levels in adults with stage 3 CKD and asymptomatic hyperuricemia but did not improve endothelial function in this sample of patients.
Details
- Title: Subtitle
- Vascular Function and Uric Acid-Lowering in Stage 3 CKD
- Creators
- Diana I Jalal - VA Eastern Colorado Health Care System, Denver, ColoradoEmily Decker - Division of Renal Diseases and Hypertension, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, ColoradoLoni Perrenoud - Division of Renal Diseases and Hypertension, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, ColoradoKristen L Nowak - Division of Renal Diseases and Hypertension, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, ColoradoNina Bispham - Department of Integrative Physiology, University of Colorado Boulder, Boulder, ColoradoTapan Mehta - Division of Renal Diseases and Hypertension, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, ColoradoGerard Smits - Division of Renal Diseases and Hypertension, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, ColoradoZhiying You - Division of Renal Diseases and Hypertension, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, ColoradoDouglas Seals - Department of Integrative Physiology, University of Colorado Boulder, Boulder, ColoradoMichel Chonchol - Division of Renal Diseases and Hypertension, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, ColoradoRichard J Johnson - Division of Renal Diseases and Hypertension, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado
- Resource Type
- Journal article
- Publication Details
- Journal of the American Society of Nephrology, Vol.28(3), pp.943-952
- DOI
- 10.1681/ASN.2016050521
- PMID
- 27620990
- PMCID
- PMC5328166
- ISSN
- 1046-6673
- eISSN
- 1533-3450
- Grant note
- K01 DK103678 / NIDDK NIH HHS K23 DK088833 / NIDDK NIH HHS
- Language
- English
- Date published
- 03/2017
- Academic Unit
- Nephrology; Internal Medicine
- Record Identifier
- 9984094313502771
Metrics
10 Record Views